OnCall Doctors: Private Healthcare for Lancashire and the Fylde Coast
Make an appointment today on 01253 834055

Any weight loss injection you encounter works through the GLP-1 hormonal mechanism. Mounjaro operates through two pathways: GLP-1 and GIP. This is no small technical difference. This makes the drug operate in a completely different way in the body, and for most people, it makes the scale readings change too. This dual-action mechanism is central to understanding Mounjaro weight loss and why it differs from some other weekly weight loss injections.
The key component in Mounjaro is Tirzepatide. This medication was initially created for type 2 diabetes. Currently, it is licensed in the UK as a drug for weight management in obese and overweight adults with other weight-related health problems. For those considering Mounjaro injections in the UK, understanding its active ingredient and intended use is an important part of assessing treatment.
GLP-1 signals the brain to feel full and also slows gastric emptying. GIP works in synergy with GLP-1 to decrease fat accumulation and enhance fat burning. Therefore, it helps diminish appetite without stimulants and maintain a caloric deficit for a prolonged period. These effects are a major reason why Mounjaro weight loss can become noticeable over the course of treatment.
Mounjaro dosage begins at 2.5 mg once per week. The dosage will increase in increments of 2.5 mg every four weeks until it reaches the maximum of 15 mg once per week. However, any dosage adjustments should be made only as your GP recommends. The initial dosage is intentionally small because most gastrointestinal side effects appear during the escalation phase, not after reaching the maintenance dosage.
Dosage changes should be prescribed only by a healthcare provider. Self-dosage escalation to accelerate Mounjaro weight loss is not recommended and does not have any therapeutic value. A comprehensive GP appointment can provide time for a proper clinical assessment before treatment decisions are made.
Individuals using Mounjaro in conjunction with diet and lifestyle modifications have experienced decreased waist circumference, reduced blood pressure and lower fasting insulin levels. For individuals with prediabetes, there have been significantly fewer cases of progression to type 2 diabetes following sustained therapy. All these physiological changes happen regardless of weight gain or loss. These broader changes can also form part of what people consider when assessing their Mounjaro results.
They include nausea, diarrhoea, constipation, vomiting, and stomach pain, and mostly develop during dosing increases. Having small portions of food, reducing consumption of fatty food products and being properly hydrated will help you decrease these side effects. Understanding potential Mounjaro side effects is an important part of making an informed decision about treatment.
It is important to mention that Mounjaro cannot be taken by patients who have had medullary thyroid carcinoma or multiple endocrine neoplasia type 2 syndrome.
Once treatment is stopped, the appetite is restored to its former state. This is normal physiology and does not indicate a failure of the treatment. Maintenance of the diet and exercise routines formed during treatment helps maintain a large amount of the weight loss attained. This is also an important consideration when evaluating Mounjaro weight loss injections in St Annes as part of a longer-term weight management approach.
All of those with contraindications listed above, pregnant women or those expecting to become pregnant, and those on drugs that interact with tirzepatide all need clinical evaluation. No prescription drug for weight loss should be prescribed without a thorough medical history. Extended consultations with your GP or weight loss medical professional can be particularly valuable when there are multiple health factors to consider.